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Abstract 
Background: Due to the limitations of more common treatments of osteoarthritis, pharmaceutical research has 
been increasingly conducted during the past two decades with the aim of determining the rate of recovery of the 
disease' symptoms and making the process of disease progression slow. The purpose of this study was to 
compare the effect of intra-articular injection of autologous interleukin-1 Receptor Antagonist and hyaluronic 
acid in pain control of knee osteoarthritis. 
Materials and Methods: A total of 60 patients with knee osteoarthritis were allocated to two groups of 30 in 
this randomized double-blind clinical trial. In the intervention group, injection of 2 milliliter of interleukin-1 
receptor antagonist (Orthokine) into the knee joint was performed three times at intervals of one week (base 
time, seventh day and fourteenth day). In the control group, three injections of two milliliters of hyaluronic acid 
solution into the knee joint were performed at intervals of one week. Pain, symptoms, daily activities, sport-
recreational performance, and knee-related quality of life were five outcomes investigated by completing two 
questionnaires, the knee injury and osteoarthritis outcome score (KOOS), Western Ontario, and McMaster 
Universities Arthritis Index (WOMAC) by the patients on two occasions before the start of treatment and six 
months after the last injection. Repeated measure and t-test were statistical tests used in this study. 
Results: The mean score of pain in the first month (p=0.005) and the sixth (p=0.049) in the intervention 
group was less than the control group. Based on the scores of the KOOS questionnaire, the mean score of 
symptoms (p=0.006), daily activities (p=0.001) and sport-recreational performance (p=0.037) in the 
Orthokine group were higher than the hyaluronic acid group after six months. Also, the results of the 
questionnaire WOMAC show that while before the start of treatment, the mean of physical performance in 
the Orthokine group is greater than the control group, there is no difference in any of the indicators of pain, 
dryness of the joint, physical performance, and total score (p=0.319) in the sixth month. 
Conclusion: According to the findings of this study, it seems that Orthokine has beneficial biological effects in 
patients with knee osteoarthritis. Intra-articular injection of Orthokine is a low invasive, safe and effective 
method, which can be considered as an appropriate choice in patients with chronic knee pain. 
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Introduction 
Osteoarthritis (OA) is degenerative joint disease with 
a slow progressive process that 10% of the world's 
population over the age of 60 years is involved with 
this disease according to the world health 
organization (WHO) estimation, and the increased 
incidence of this disease will be expected due to the 
increasing elderly in many parts of the world1. Not 
only is osteoarthritis today one of the most common 
causes of clinical referrals of the elderly, but also 
makes the younger people involve after trauma 
or popular heavy sports2-4. Destruction of articular 
cartilage, remodeling of subchondral bones and 
synovitis are the most important causes of OA5 
which consequently lead to the pain, reduced the 
range of joint movement, inflammation and swelling 
of the joint, involvement of total structure of the 
joint, cartilage, bone, ligament and muscle and 
ultimately lead to the patients' disability6-8. 
Modifying daily activities, physical treatment, 
consuming anti-inflammatory drugs, cryotherapy, 
hyperthermia, injection into the knee joint and 
arthroplasty are some of the treatment methods for 
OA control, which improve knee pain7,9. Although 
low invasive treatments such as injection of steroid 
into the knee, lignocaine, hyaluronic acid10, non-
steroidal anti-inflammatory and cyclooxygenase-2 
inhibitors drugs11,12 have been reported to be 
effective in reducing pain and knee joint function. 
They do not prevent the progress of the disease and 
will have important consequences such as upper 
gastrointestinal bleeding and cardiovascular ischemia 
in the long-term consumption13,14. Due to the 
limitations of more common treatments, 
pharmaceutical research has been increasingly 
designed and implemented during the past two 
decades with the aim of determining the rate of 
recovery of the disease' symptoms. Making the 
process of disease progression slow as well as 
preventing the need to arthroplasty using disease 
modifying osteoarthritis drugs (DMOADs) assuming 
the effect of intervention in the pathway of pro-
inflammatory cytokines such as 1-β (IL-1β)15. 
Autologous conditioned serum (ACS) is one of the 
new methods of no-cell therapy which was developed 
in the mid-1990s. In this method, a significant amount 
of anti-inflammatory cytokines is produced including 
interleukin-1 receptor antagonist (IL-1Ra), IL-4, IL-10 
and regenerative growth factors including TGF-β 
using the patient's venous blood process16,17. 
Orthokine (IL-1Ra) is the product of the patient' 
complete blood, which is incubated with glass grains 
covered with CrSO4 and improves pain and 
inflammation by blocking the destructive proteins 
which leads to the maintenance of the joint health18. 
Considering that a few human and animal studies have 
been conducted on the effectiveness of Orthokine in 
reducing the symptoms and reducing the progression 
rate of OA and no study has been conducted in Iran to 
compare the effectiveness of this treatment compared 
with other treatments. So far, the purpose of this study 
was to compare the effect of intra-articular injection of 
autologous interleukin-1 receptor antagonist and 
hyaluronic acid in pain control of knee osteoarthritis. 
Methods 
Study Design: This study was a randomized double-
blind clinical trial to compare the effect of intra-
articular injection of autologous interleukin-1 receptor 
antagonist and hyaluronic acid in pain control of 60 
patients with knee osteoarthritis at the time of 
treatment, three and six months after treatment. The 
sampling method was sequential therefore; all eligible 
people referred respectively, and were selected to 
complete the desired sample size. For randomization 
of patients into two groups, we used balanced block 
method and then informed consent has been obtained 
from the patients.  
Patients: Patients with knee osteoarthritis referring to 
pain clinic of Shohadaye Tajrish and Akhtar hospitals 
in Tehran were entered the study. The study included 
the patients who were 40-year old and older that they 
had knee osteoarthritis pain for more than three 
months. Radiological findings confirmed knee 
osteoarthritis based on the American College of 
Rheumatology (ACR) criteria, and were satisfied to 
participate in the study. Exclusion criteria were 
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included patients with a history of knee surgery, 
lower limb contracture and deformity, neuromuscular 
disease of the lower limb, acute lumbar pathology, 
injection of steroid drugs during the last two months, 
the history of inflammatory rheumatoid arthritis, 
infection, diabetes, pregnancy, lactation, 
BMI˃35, anticoagulant drugs consumption, allergic 
to any of drugs, patients candidate for knee surgery, 
varus or valgus knee more than five degrees which 
had been confirmed by the three joint view graph, 
radicular pain in knee, post-traumatic arthritis, the 
history of intra-articular injection or ozone therapy 
during the past 12 months, systemic or psychiatric 
disease, severe osteoarthritis with grade over III, 
intra-articular injection of hyaluronic acid during the 
past 12 months, Hepatitis, AIDS, cytomegalovirus, 
syphilis, osteomyelitis, drug and alcohol abuse, and 
the lack of consent to participate in the project. 
Drug administration: Patients were randomized 
into two groups receiving 2 ml of IL-1RA 
(intervention group) and receiving 2 ml of hyaluronic 
acid (control group). To prepare IL-1RA, in the 
intervention group, 10 ml of venous blood was taken 
from the patient using the orthokine syringe 
(manufacturing country: Germany, manufacturing 
company: Orthokine), which contains glass grains 
covered with CrSO4. The syringe was slowly rotated 
and immediately stored at 37°C and transferred to a 
single laboratory in a special incubator within 24 
hours to ensure complete mixing and maximum grain 
and blood contact. After making sure the tests are 
negative for HIV, and hepatitis A, B and C, the 
products of Orthokine (IL-1RA) were prepared by a 
single laboratory and were returned to the hospital in 
2 ml vials at -20°C within 14-21 days. Protocol of 
diet therapy was included 3 injections at intervals of 
one week that were performed on the first day, 7 and 
14 days after the first injection. In the control group, 
2 ml of hyaluronic acid was injected into the knee 
joint that three injections were also performed in 
these patients at intervals of one week. To do the 
procedure, the patient was placed in supine position 
and the landmark of the injection site was determined 
with flexion of the knee of 30-45 degrees on the 
lateral side of the knee. The injection site was 
disinfected with Povidone iodine solution and two 
milliliters of 2% Lidocaine solution were injected 
using a needle No. 27 for numbness of the skin and 
joint surface to enter the needle without pain. After 
aspiration and ensuring, the correct positioning of the 
needle by ultrasound guidance (Sono Site, PICO. 
probe Convex 3-7, Linear 5-12), IL-1RA / hyaluronic 
acid was injected into the joint using the same needle. 
During the study, patients did not consume steroid, 
antidepressant and sedation drugs and they could 
consume acetaminophen (Maximum 4 grams per day) 
in case of incidence of pain with a score of over 3 
during the study. 
Measurement and Tools: Pain, symptoms, daily 
activities, sport-recreational performance, and knee-
related quality of life were five outcomes, which were 
investigated that its required information was obtained 
by completing two questionnaires Knee injury and 
osteoarthritis outcome score (KOOS) and WOMAC by 
the patient on two occasions before the start of 
treatment and six months after the last injection. The 
questionnaire KOOS uses a 4-point Likert scale (4-0) 
to respond and includes pain (the highest raw score of 
36), symptoms (the highest raw score of 28), daily 
activities (the highest raw score of 68), sport-
recreational performance (the highest raw score of 20) 
and quality. The questionnaire WOMAC uses a 5-
point Likert scale (5-0) to respond and has three 
sections: assessment of pain (5 questions, the highest 
raw score of 36), dryness of the joint (2 questions, the 
highest raw score of 28), and physical performance 
(17 questions, the highest raw score of 68). 
Ethical approval: The study protocol was approved 
by the Institutional Research Ethics Committee of 
Shahid Beheshti University of Medical Sciences, 
Tehran, Iran and was conducted according to the 
stated principles in the Declaration of Helsinki 
(Ethical code: IR.SBMU.RETECH.REC.1397.835; 
date: 2019-01-06) 
Data analysis: Chi-squared (X2), t-test, paired t-test 
and repeated measurement ANOVA were used to 
compare patient characteristics which were treated 
byIL-1Ra or Hyaluronic Acid. Data were analyzed 
using SPSS 16 software, with a probability (P) value 
of less than 0.05 as statistically significant. 
Results 
Patient characteristics: The characteristics of the 60 
patients enrolled were shown in Table 1. In short, the 
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mean age in two intervention and control groups was 
56 and 57 years, and 36.7% of the patients receiving 
Orthokine and 46.7% of the patients receiving 
hyaluronic acid group were with Grade II 
osteoarthritis. In addition, 63.3% and 53.3% in two 
groups were with Grade III. 
Outcome measurement: As shown in Table 2, the 
mean score of pain in the first and sixth months in 
the intervention group is lower than in the control 
group. However, the analysis of repeated measure 
showed that there was no significant difference 
between the two groups in terms of the changes in 
the amount of pain before the start of treatment, one 
month, three months and six months after treatment 
based on VAS score (p=0.319) (Figure 1). 
Comparison of KOOS scores before the start of 
treatment and six months after treatment in two 
groups based on the score of pain, symptoms, daily 
activities, sport-recreational activities and quality of 
life is shown in Table 3. Accordingly, the mean score 
of symptoms, daily activities, and sport-recreational 
activities in the control group before the start of 
treatment were significantly higher than the 
intervention group; while, this relationship was 
reversed after six months and the mean scores of these 
three indicators in the IL-1Ra group was higher than 
the hyaluronic acid group. In addition, the results of 
the questionnaire WOMAC showed that while before 
the start of treatment, the mean of physical 
performance in the group Orthokine was greater than 
the control group, there was no difference in any of the 
indicators of pain, dryness of the joint, physical 
performance, and total score in the sixth month 
(p=0.319). 
Discussion 
In the present study, there was a significant decrease in 
the amount of pain six months after treatment in the 
Orthokine group based on VAS score. However, these 
changes did not show significant differences between 
the two groups at different times. In addition, KOOS 
pain score was higher in the Orthokine group six 
months after treatment and there was a further 
decrease in the amount of pain and there was a further 
decrease in the amount of pain, but there was no 
significant difference compared to the hyaluronic acid 
group. Based on the criteria KOOS, our findings 
showed that there was a significant improvement in 
the scores of symptoms, daily activities, and sport-
recreational activities in the Orthokine group. In 
addition, the scores of pain, dryness of the joint, 
physical activity, and total scores of WOMAC were 
higher in the Orthokine group and the patients had 
greater improvement compared to the hyaluronic acid, 
but comparison of the two groups did not show 
statistically significant difference. The treatment of 
osteoarthritis surgery has good results, but it is not the 
best option for the treatment of osteoarthritis in many 
cases due to the dangers of surgery and the patients' 
unwillingness to do so19. Therefore, over the past 
decades, many physicians have taken the use of drug 
therapies, which can change the process of disease 
progression and probably lead to delay or prevent 
surgical interventions, into consideration. The findings 
of our study, which are consistent with the results of 
similar studies, showed that improvement of 
symptoms in the group receiving Orthokine is more 
than the control group 20-23. In a double blind clinical 
trial in comparing Orthokine with hyaluronic acid and 
normal saline for the first time in 2009, Baltzer et al,24 
Table 1: Baseline demographics of study subjects. 
Characteristics IL-1Ra Hyaluronic 
Acid 
Number ofpatients 30 30 
Age (years)a 56.8±8.6 57.9±8.2 
Male/female 14/16 9/21 
Weight(Kg) 81.6±9.7 81.6±7.9 
Height(cm) 164.8±6.3 162.2±6.7 
BMI 31.3±2.4 30.4±3.5 
Grade of osteoarthritis   
II 11(36.7%) 14(46.7%) 
III 19(63.3%) 16(53.3%) 
Job   
employee 12(40%) 15(50%) 
housewife 13(43.3%) 13(43.3%) 









Baseline 5.6±1.0 5±8.5 0.262 
1months 3.3±0.5 3±7.5 0.005 
3 months 2.7±0.6 2±9.5 0.16 
6 months 2.9±0.6 2±5.6 0.049 
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showed that reduction of symptoms and improvement of quality of life in patients receiving 
Table 3: Comparison of scores in two group at baseline and six months after treatment. 
Questioner Time of 
treatment 
Type of score HA Orthockine P-Value 
KOOS  Baseline Pain score 46.9±10.4 40.1±8.9 0.317 
Sign score 46.9±10.4 41.9±2.5 0.035 
Daly activities score 52.9±8.9 37.9±8.1 0.001 
Sport and recreation score 29.8±13.4 22.7±3.5 0.002 
Quality of life 27.1±0.0 23.1±4.1 0.337 
6 months Pain score 70.8±9.4 71.0±8.8 0.957 
Sign score 63.8±1.0 71.7±14.3 0.006 
Daly activities score 59.9±1.4 72.6±9.2 0.001 
Sport and recreation score 46.7±7.9 52.5±13 0.037 
Quality of life 44.1±8.6 46.1±9.4 0.483 
WOMAC 
 
Baseline Pain score 43.5±16.0 46.1±0.5 0.548 
Dryness of the joint 41.4±14.9 45.9±6.5 0.199 
Physical function 22.8±9.4 45.1±2.2 0.001 
Total score 107±7.6 136.3±8.8 0.005 
6 months Pain score 68.1±10.9 69.1±7.8 0.339 
Dryness of the joint score 55.4±10.1 58.8±2.6 0.253 
Physical function score 71.5±10.7 71.3±3.2 0.836 





Figure 1. Mean of VAS scores based on time in two groups. 
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Orthokine were significantly higher than the 
hyaluronic acid group after 104 weeks of follow-up. 
This is while the researchers of this study did not 
observe any difference between the two groups of 
hyaluronic acid and normal saline. Similar findings 
observed in the study by Astolfi et al, in 201425. In a 
quasi-experimental study was done on 118 patients 
with knee osteoarthritis with chronic pain and 
candidate for the surgery, the researchers showed that 
regarding the patients who had been treated with 
ACS, the knee joint was replaced only in one person 
after 24 months and there was more than 60% to 80% 
improvement in pain in other patients. In addition, 
the duration of analgesia and the ACS therapeutic 
effects were long lasting and the patients tolerated 
this treatment well17. Few studies have also shown 
that there was no significant difference in 
improvement of clinical symptoms of knee 
osteoarthritis in the two groups of Orthokine and 
normal saline26. While, it was shown in animal 
studies from the 1980s intra-articular injection of IL-
1RA into the animal's knee leads to reduce the 
process of osteoarthritis progression and the level of 
IL-1RA is increased from a few weeks to several 
months after treatment27-29. In the first human 
studies, intra-articular injection of IL-1RA with a 
half-life of approximately 4 hours after injection in 
patients with painful knee did not lead to the clinical 
improvement of symptoms of osteoarthritis30. 
Differences in the inclusion criteria of the study, 
tools used to measure, duration of patients' follow-
up, long effect of placebo, and behavioral change of 
patients can be mentioned as the most important 
reasons for the difference in the results. Auw Yang et 
al,20 showed that the KOOS score was significantly 
less than the score obtained in the study by 
Paradowski et al,31 with the same age group of 
patients. Also in studies by Waddell et al,32 and 
Altman et al,33 that Orthokine was compared to 
hyaluronic acid, the number of patients treated with 
Orthokine without need for surgery was high. 
Furthermore, the perception of patients with 
osteoarthritis of their health status and symptoms of 
osteoarthritis will be changed with the passage of 
time and significantly affect the evaluation of the 
effect of therapeutic interventions34. The severity of 
osteoarthritis plays an important role in response to 
the treatment of Orthokine. The results of the study by 
Frizziero A et al,35 showed that ACS containing anti-
inflammatory endogenous cytokines includes IL-1RA 
and several growth factors which reduces the pain and 
increases the function and motion of knee in mild to 
moderate knee osteoarthritis. According to their 
findings, the use of ACS in the treatment of 
osteoarthritis is effective and safe and can increase the 
tissue regeneration and reduce the degenerative 
mechanisms. Also, the findings of another study that 
patients were followed-up more than seven years 
showed that the use of Orthokine in patients with end 
stages of knee osteoarthritis did not lead to delay in the 
surgical treatment and more than 40% of the patients 
receiving Orthokine received surgical treatment36. 
Conclusion 
According to the findings of this study, it seems that 
Orthokine has beneficial biological effects in patients 
with knee osteoarthritis. Intra-articular injection of 
Orthokine is a low invasive, safe and effective method, 
which can be considered as an appropriate choice in 
patients with chronic knee pain. Thus, it is 
recommended to the pain specialists, orthopedic 
surgeons and rheumatologists to consider using 
therapeutic protocol of Orthokine according to the diet 
therapy of our study. It is suggested to conduct this 
study with larger sample size and longer follow up 
time and compared to the other drugs and placebo in 
future as well as to use other tools to evaluate the 
results of treatment and improvement of knee joint 
performance in addition to the KOOS and WOMAC 
tools. 
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